Patents by Inventor Martin Friede
Martin Friede has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110243971Abstract: The invention relates to a vaccine composition comprising an antigen, an immunologically active saponin fraction and a sterol.Type: ApplicationFiled: June 16, 2011Publication date: October 6, 2011Inventors: Martin Friede, Nathalie Garcon
-
Publication number: 20100183652Abstract: A method of treating chronic hepatitis B is disclosed that comprises administering a T cell-stimulating amount of a vaccine to a patient. The vaccine comprises an immunogenic amount of chimeric, carboxy-terminal truncated hepatitis B virus nucleocapsid (core) protein (HBc) that is engineered for both enhanced stability of self-assembled particles and the substantial absence of nucleic acid binding by those particles. The chimeric protein molecule can include one or more immunogenic epitopes peptide-bonded to one or more of the N-terminus, the immunogenic loop or the C-terminus of HBc. The enhanced stability of self-assembled particles is obtained by the presence of at least one heterologous cysteine residue near one or both of the amino-terminus and carboxy-terminus of the chimer molecule.Type: ApplicationFiled: March 14, 2008Publication date: July 22, 2010Inventors: Mark Page, Martin Friede, Annette Elisabeth Schmidt, Detlef Stober
-
Publication number: 20090155309Abstract: The invention relates to the use of a non-live influenza virus antigen preparation, particularly a split influenza virus preparation, in the manufacture of a vaccine formulation for a one-dose intranasal vaccination against influenza, wherein the one-dose vaccination meets international regulatory requirements for influenza vaccines. Further provided are methods for the production of the vaccine, and a pharmaceutical kit comprising an intranasal administration device and the one-dose vaccine.Type: ApplicationFiled: February 18, 2009Publication date: June 18, 2009Inventors: Martin Friede, Veronique Henderickx, Philippe Hermand, Moncef Mohamed Saloui, Sefan Gabriel Jozef Thoelen
-
Publication number: 20080311156Abstract: The present invention relates to adjuvant compositions which are suitable to be used in vaccines. In particular, the adjuvant compositions of the present invention comprises a saponin and an immunostimulatory oligonucleotide, optionally with a carrier. Also provided by the present invention are vaccines comprising the adjuvants of the present invention and an antigen. Further provided are methods of manufacture of the adjuvants and vaccines of the present invention and their use as medicaments. Methods of treating an individual susceptible to or suffering from a disease by the administration of the vaccines of the present invention are also provided.Type: ApplicationFiled: July 11, 2008Publication date: December 18, 2008Inventors: Martin FRIEDE, Nathalie Garcon, Catherine Marie Ghislaine Gerard, Philippe Hermand
-
Patent number: 7399472Abstract: The present invention relates to adjuvant compositions which are suitable to be used in vaccines. In particular, the adjuvant compositions of the present invention comprises a saponin and an immunostimulatory oligonucleotide, optionally with a carrier. Also provided by the present invention are vaccines comprising the adjuvants of the present invention and an antigen. Further provided are methods of manufacture of the adjuvants and vaccines of the present invention and their use as medicaments. Methods of treating an individual susceptible to or suffering from a disease by the administration of the vaccines of the present invention are also provided.Type: GrantFiled: March 3, 2003Date of Patent: July 15, 2008Assignee: Smithkline Beecham BiologicalsInventors: Martin Friede, Nathalie Garcon, Catherine Marie Ghislaine Gerard, Philippe Hermand
-
Publication number: 20080095788Abstract: The present invention relates to adjuvant compositions which are suitable to be used in vaccines. In particular, the adjuvant compositions of the present invention comprises a saponin and an immunostimulatory oligonucleotide, optionally with a carrier. Also provided by the present invention are vaccines comprising the adjuvants of the present invention and an antigen. Further provided are methods of manufacture of the adjuvants and vaccines of the present invention and their use as medicaments. Methods of treating an individual susceptible to or suffering from a disease by the administration of the vaccines of the present invention are also provided.Type: ApplicationFiled: December 20, 2007Publication date: April 24, 2008Inventors: Martin Friede, Nathalie Garcon, Catherine Gerard, Philippe Hermand
-
Patent number: 7351413Abstract: A method of treating chronic hepatitis B is disclosed that comprises administering a T cell-stimulating amount of a vaccine to a patient. The vaccine comprises an immunogenic amount of chimeric, carboxy-terminal truncated hepatitis B virus nucleocapsid (core) protein (HBc) that is engineered for both enhanced stability of self-assembled particles and the substantial absence of nucleic acid binding by those particles. The chimeric protein molecule can include one or more immunogenic epitopes peptide-bonded to one or more of the N-terminus, the immunogenic loop or the C-terminus of HBc. The enhanced stability of self-assembled particles is obtained by the presence of at least one heterologous cysteine residue near one or both of the amino-terminus and carboxy-terminus of the chimer molecule.Type: GrantFiled: October 1, 2003Date of Patent: April 1, 2008Assignee: Lorantis, LimitedInventors: Mark Page, Martin Friede, Annette Elisabeth Schmidt, Detlef Stober
-
Publication number: 20050214322Abstract: The invention relates to a vaccine composition comprising an antigen, an immunologically active saponin fraction and a sterol.Type: ApplicationFiled: October 18, 2004Publication date: September 29, 2005Inventors: Nathalie Claude Garcon, Martin Friede
-
Publication number: 20050214285Abstract: The present invention relates to the provision of novel medicaments for the treatment, prevention or amelioration of allergic disease. In particular, the novel medicaments are isolated peptides incorporating epitopes or mimotopes of surface exposed regions of the C?2 domain of IgE. The inventors have found that these novel regions may be the target for both passive and active immunoprophylaxis or immunotherapy. The invention further relates to methods for production of the medicaments, pharmaceutical compositions containing them and their use in medicine. Also forming an aspect of the present invention are ligands, especially monoclonal antibodies, which are capable of binding the surface exposed IgE regions of the present invention, and their use in medicine as passive immunotherapy or in immunoprophylaxis.Type: ApplicationFiled: December 7, 2004Publication date: September 29, 2005Inventors: Michael Dyson, Martin Friede, Judith Greenwood, Ellen Hewitt, Alan Lamont, Sean Mason, Roger Randall, William Turnell, Marcelle Van Mechelen, Carlotta y de Bassols
-
Publication number: 20050201946Abstract: Aminopiperidine derivatives and pharmaceutically acceptable derivatives thereof are disclosed. Such derivatives are useful in methods of treatment of bacterial infections in mammals, particularly in man.Type: ApplicationFiled: May 2, 2005Publication date: September 15, 2005Inventors: Martin Friede, Veronique Henderickx, Philippe Hermand, Moncef Slaoui, Stefan Thoelen
-
Publication number: 20050152892Abstract: The present invention relates to the provision of novel medicaments for the treatment, prevention or amelioration of allergic disease. In particular, the novel medicaments are epitopes or mimotopes derived from the C?3 or C?4 domains of IgE. These novel regions may be the target for both passive and active immunoprophylaxis or immunotherapy. The invention further relates to methods for production of the medicaments, pharmaceutical compositions containing them and their use in medicine. Also forming an aspect of the present invention are ligands, especially monoclonal antibodies, which are capable of binding the IgE regions of the present invention, and their use in medicine as passive immunotherapy or immunoprophylaxis.Type: ApplicationFiled: December 3, 2004Publication date: July 14, 2005Inventors: Martin Friede, Sean Mason, William Turnell, Marcelle Van Mechelen, Carlotta de Bassols
-
Patent number: 6846489Abstract: A novel adjuvant composition comprising a sterol (e.g., cholesterol, ?-sitosterol, stigmasterol, ergosterol, and ergocalciferol) and saponin fraction (e.g., QS21, also known as QA21) in the form of an immunostimulating complex, or ISCOM, is disclosed. QS21 is an immunologically active saponin fraction having adjuvant activity derived from the bark of Quillaja Saponaria Molina. Previous attempts in the prior art to prepare ISCOMs comprising QS21 were unsuccessful. Thus, the instant application discloses the first successful attempt to prepare ISCOMs comprising purified QS21. Small unilamelar liposomes containing cholesterol, in the absence of any detergent, were prepared, followed by the addition of an aqueous solution of QS21. The claimed compositions will prove useful in the preparation of highly immunogenic vaccine compositions.Type: GrantFiled: January 6, 2000Date of Patent: January 25, 2005Assignee: SmithKline Beecham Biologicals s.a.Inventors: Nathalie Marie-Josephe Claude Garcon, Martin Friede
-
Publication number: 20040156863Abstract: A method of treating chronic hepatitis B is disclosed that comprises administering a T cell-stimulating amount of a vaccine to a patient. The vaccine comprises an immunogenic amount of chimeric, carboxy-terminal truncated hepatitis B virus nucleocapsid (core) protein (HBc) that is engineered for both enhanced stability of self-assembled particles and the substantial absence of nucleic acid binding by those particles. The chimeric protein molecule can include one or more immunogenic epitopes peptide-bonded to one or more of the N-terminus, the immunogenic loop or the C-terminus of HBc. The enhanced stability of self-assembled particles is obtained by the presence of at least one heterologous cysteine residue near one or both of the amino-terminus and carboxy-terminus of the chimer molecule.Type: ApplicationFiled: October 1, 2003Publication date: August 12, 2004Inventors: Mark Page, Martin Friede, Annette Elisabeth Schmidt, Detlef Stober
-
Publication number: 20040030106Abstract: The present invention relates to a novel chemical process for the covalent conjugation of disulphide bridge cyclised peptides to immunogenic carrier molecules by thio-ether linkages to form vaccine immunogens. In particular, the novel chemistry involves reacting a thiolated carrier with a cyclic peptide containing a disulphide bridge, which cylcic peptide (herein a disulphide bridge cyclised peptide) has attached to it, usually via a linker, a reactive group capable for forming thio-ether bonds with the carrier. The invention further related to activated peptide intermediates of the process, medicaments produced by the process, pharmaceutical compositions containing the medicaments, and the use of the pharmaceutical compositions in medicine. The process of the present invention is particularly useful for the preparation of highly pure immunogens for vaccines, comprising disulphide bridge cyclised peptides.Type: ApplicationFiled: July 30, 2003Publication date: February 12, 2004Inventors: Martin Friede, Sean Mason, William Gordon Turnell, Carlota Vinals Y De Bassols
-
Publication number: 20030198645Abstract: A method of treating chronic hepatitis B is disclosed that comprises administering a T cell-stimulating amount of a vaccine to a patient. The vaccine comprises an immunogenic amount of chimeric, carboxy-terminal truncated hepatitis B virus nucleocapsid (core) protein (HBc) that is engineered for both enhanced stability of self-assembled particles and the substantial absence of nucleic acid binding by those particles. The chimeric protein molecule can include one or more immunogenic epitopes peptide-bonded to one or more of the N-terminus, the immunogenic loop or the C-terminus of HBc. The enhanced stability of self-assembled particles is obtained by the presence of at least one heterologous cysteine residue near one or both of the amino-terminus and carboxy-terminus of the chimer molecule.Type: ApplicationFiled: February 21, 2003Publication date: October 23, 2003Inventors: Mark Page, Martin Friede
-
Publication number: 20030170229Abstract: The present invention relates to the provision of novel medicaments for the treatment, prevention or amelioration of allergic disease. In particular, the novel medicaments are epitopes or mimotopes derived from the C&egr;3 or C&egr;4 domains of IgE. These novel regions may be the target for both passive and active immunoprophylaxis or immunotherapy. The invention further relates to methods for production of the medicaments, pharmaceutical compositions containing them and their use in medicine. Also forming an aspect of the present invention are ligands, especially monoclonal antibodies, which are capable of binding the IgE regions of the present invention, and their use in medicine as passive immunotherapy or immunoprophylaxis.Type: ApplicationFiled: November 26, 2002Publication date: September 11, 2003Applicant: SmithKline Beecham Biologicals s.a.Inventors: Martin Friede, Sean Mason, William G. Turnell, Carlota Vinals y de Bassols, Marcelle Paulette Van Mechelen
-
Publication number: 20030161834Abstract: The present invention relates to adjuvant compositions which are suitable to be used in vaccines. In particular, the adjuvant compositions of the present invention comprises a saponin and an immunostimulatory oligonucleotide, optionally with a carrier. Also provided by the present invention are vaccines comprising the adjuvants of the present invention and an antigen. Further provided are methods of manufacture of the adjuvants and vaccines of the present invention and their use as medicaments. Methods of treating an individual susceptible to or suffering from a disease by the administration of the vaccines of the present invention are also provided.Type: ApplicationFiled: March 3, 2003Publication date: August 28, 2003Applicant: SmithKline Beecham Biologicals s.a.Inventors: Martin Friede, Nathalie Garcon, Catherine Marie Ghislaine Gerard, Philippe Hermand
-
Publication number: 20030147906Abstract: The present invention relates to the provision of novel medicaments for the treatment, prevention or amelioration of allergic disease. In particular, the novel medicaments are epitopes or mimotopes derived from the C&egr;3 or C&egr;4 domains of IgE. These novel regions may be the target for both passive and active immunoprophylaxis or immunotherapy. The invention further relates to methods for production of the medicaments, pharmaceutical compositions containing them and their use in medicine. Also forming an aspect of the present invention are ligands, especially monoclonal antibodies, which are capable of binding the IgE regions of the present invention, and their use in medicine as passive immunotherapy or immunoprophylaxis.Type: ApplicationFiled: December 18, 2002Publication date: August 7, 2003Applicant: SmithKline Beecham Biologicals, s.a.Inventors: Martin Friede, Sean Mason, WIlliam Gordon Turnell, Marcelle Paulette Van Mechelen, Carlotta Vinals y de Bassols
-
Patent number: 6558670Abstract: The present invention relates to adjuvant compositions which are suitable to be used in vaccines. In particular, the adjuvant compositions of the present invention comprises a saponin and an immunostimulatory oligonucleotide, preferably the saponins used in said adjuvant combinations are haemolytic. Also provided by the present invention are vaccines comprising the adjuvants of the present invention and an antigen. Further provided are methods of manufacture of the adjuvants and vaccines of the present invention and their use as medicaments.Type: GrantFiled: April 29, 1999Date of Patent: May 6, 2003Assignee: SmithKline Beechman Biologicals s.a.Inventors: Martin Friede, Philippe Hermand
-
Publication number: 20030072768Abstract: This invention provides a method to enhance an immune response of nucleic acid vaccination by simultaneous administration of a polynucleotide and a polypeptide of interest.Type: ApplicationFiled: November 12, 2002Publication date: April 17, 2003Applicant: SmithKline Beecham Biologicals, s.a.Inventors: Wilfried Dalemans, Marcelle Van Mechelen, Claudine Bruck, Martin Friede